|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
CoreValve completes $33 million private financing
April 2nd, 2007 No comments
CoreValve, a medical device company developing technologies for percutaneous heart valve replacement, announced recently that it received $33 million in funding in its third institutional round of financing. Maverick Capital led the round and was joined by existing investors Apax Partners, HealthCap, and Sofinnova Partners.
“We have made significant progress in the development of our core technologies as well as in our clinical programs,” said Jacques Sguin, M.D., Ph.D., Chairman, CEO and Founder of CoreValve.
“This additional capital enables us to continue the execution of our strategy of leadership in less invasive heart valve delivery systems and the expansion of worldwide clinical trials.”
Since the early 1960’s, valve replacement surgery has extended the lives of people with failing aortic heart valves. Unfortunately, valve replacement surgery currently requires accessing the chest and opening the heart. Many patients are simply too ill to be considered as candidates for this type of invasive surgery.
Working with leading interventional cardiologists and heart surgeons, CoreValve has developed a proprietary system which permits aortic valve replacement on a beating heart in a procedure performed entirely in the cardiac catheterization laboratory. This new technology completely eliminates the need for open-chest surgery and any form of cardiac support during the aortic valve replacement procedure. These advances are expected to make heart valve replacement available to patients previously ineligible for this life-saving therapy.
Founded in 2001, privately held CoreValve – which is headquartered in Irvine, California – has developed a proprietary delivery system and tissue heart valve for percutaneous heart valve replacement. Based on a novel catheter-and-self-expanding-frame approach on a beating heart, the proprietary Co reValve ReValving System™ procedure is intended to avoid open-heart surgery. It can be performed in a cardiac “cath lab” just like angioplasty and stenting, which may result in less trauma to the patient and may offer substantial cost-savings to the healthcare system.
For more information, please visit www.corevalve.com
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility